By Michael Erman and Bhanvi Satija (Reuters) -Pfizer reported a surprise quarterly profit on Tuesday, helped by cost cuts and higher-than-expected demand for its COVID treatment Paxlovid, but sales of some high profile products fell short of Wall Street estimates. The New York-based drugmaker earned 10 cents per share on an adjusted basis for the fourth quarter. Analysts on average had expected a loss of 22 cents per share, according to LSEG data. Pfizer shares were off less than 1% in midday trading. Investors fled Pfizer last year as pandemic worries declined and billions of dollars in COVID…